11 December 2024 | News
Funds will be utilised for technology development and clinical validation
Neuranics, a healthcare diagnostics startup, has successfully raised $700K funding in a seed round led by Inflection Point Ventures (IPV). The funds will be utilised for technology development and clinical validation, enabling the company to accelerate its mission to revolutionize blood diagnostics.
Neuranics is developing a point-of-care blood analyser capable of delivering complete blood count (CBC) results in less than 10 minutes using just a finger-prick sample. The device, designed for primary and emergency settings, offers low maintenance and high efficiency, making it a game-changer for the healthcare industry.
Having accurate CBC results available immediately at the point of care, while the physician is still with the patient, allows for better-informed decisions regarding triage, additional testing, and treatment as delays are no longer caused by transport and preparation of clinical samples.
This approach benefits not only the patient, who experiences improved outcomes, but also the physician, who can diagnose, triage, and treat with greater confidence. Society also reaps the rewards through reduced healthcare costs and enhanced quality care. Unnecessary, costly, and potentially harmful medications, such as inappropriate antibiotics, can be avoided. At the same time, life-saving treatments for critical conditions like sepsis, severe anemia, and thrombocytopenia, especially in dengue patients, can be initiated promptly, ensuring timely and effective care.
With their compact dry haematology design and efficiency in delivering results directly at the point of care, Neuranics is ideally suited to address this need effectively.
Founded in 2021 by Praveen Kumar (Co-founder & CEO) and Ashutosh Patra (Co-founder & CTO), Neuranics addresses critical gaps in diagnostics, particularly in primary screening. Praveen, an IIT Delhi graduate, brings extensive experience in healthcare technology, having previously worked with the government on projects like Corona Kavach and Aarogya Setu. Ashutosh, an alumnus of the SiB(Previously Stanford India Biodesign) Program at AIIMS, leads product innovation at Neuranics with expertise in optical sensing technologies and mechanical engineering.
The company has achieved significant milestones, including a patent granted, receiving the CDSCO Test License, Ethical Approval from AIIMS Delhi, and progressing through clinical trials.